Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs …
Oct 30, 2024 · The results could help Biogen start to restore investor confidence. The stock is down 29% this year as of Tuesday’s close, largely due to a sluggish start for Leqembi — on the market to treat ...
Biogen and Neomorph Announce Multi-Target Research …
Oct 29, 2024 · News; Home; Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases ... About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to …
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
5 days ago · Biogen reported this week that sales of the drug reached $67 million in the third quarter – including $39 million in the US – which fell short of the company's expectations.
Biogen optimistic as new products gain traction
Oct 30, 2024 · On Wednesday, the Massachusetts-based biotechnology company raised its diluted earnings per share guidance for the year. That metric, which reflects the profit made for each share of a company’s common stock, is now in the range of $16.10 to $16.60, up from a previous estimate of $15.75 to $16.25. Biogen disclosed the raise in its latest ...
Biogen tops estimates, raises profit guidance as Alzheimer’s drug ...
Oct 30, 2024 · Biogen booked sales of $2.47 billion for the quarter, which is down around 3% from the year-earlier period. The drugmaker posted net income of $388.5 million, or $2.66 per share, for the period ...
Biogen Reports Third Quarter 2024 Results | Biogen
Oct 30, 2024 · Biogen Reports Third Quarter 2024 Results. Biogen Reports Third Quarter 2024 Results. October 30, 2024. Biogen Reports Third Quarter 2024 Results 465.4 KB. Stockholder Communications. E-mail Alerts. FAQs. Learn more about our Events & Presentations.
News - Biogen
Biogen News Releases and Company Statements. Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status.
Biogen Inc. Raises 2024 Financial Outlook Amid ... - Markets Insider
6 days ago · Biogen’s third-quarter 2024 earnings report shows revenue of $2.5 billion, with a GAAP diluted EPS of $2.66 and a Non-GAAP diluted EPS of $4.08. The company has raised its full-year 2024 ...
Biogen raises 2024 outlook on strong Alzheimer's drug sales
Oct 30, 2024 · Biogen (Nasdaq: BIIB) now expects its 2024 adjusted earnings per share to be between $16.10 and $16.60, up from its previous range of $15.75 to $16.25. This update comes as Biogen sees an increase ...
Biogen completes $1.15bn HI-Bio acquisition to expand …
Jul 3, 2024 · GLDAF. As Eli Lilly’s Kisunla (donanemab) enters the Alzheimer's treatment space, its leading competitor Biogen is undergoing therapy diversification after completing its $1.15bn acquisition of...
- Some results have been removed